EcoR1 Capital’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

EcoR1 Capital’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,385,873	Closed	-$2.05M	–	67
2023 Q4	$2.05M	Sell	2,385,873 -4,049,645	-63%	-$3.56M	0.05%	43
2023 Q3	$6.89M	Hold	6,435,518	–	–	0.23%	38
2023 Q2	$16.7M	Hold	6,435,518	–	–	0.41%	29
2023 Q1	$26.3M	Hold	6,435,518	–	–	0.85%	18
2022 Q4	$32.3M	Buy	6,435,518 +5,894,410	+1,089%	+$36.9M	0.98%	17
2022 Q3	$7.08M	Hold	541,108	–	–	0.21%	40
2022 Q2	$6.94M	Hold	541,108	–	–	0.24%	44
2022 Q1	$8.25M	Buy	+541,108	New	+$8.44M	0.26%	45
2021 Q3	–	Sell	-143,567	Closed	-$3.16M	–	79
2021 Q2	$2.83M	Hold	143,567	–	–	0.11%	49
2021 Q1	$4.17M	Hold	143,567	–	–	0.19%	45
2020 Q4	$4.35M	Buy	+143,567	New	+$3.14M	0.23%	44
2019 Q3	–	Sell	-316,900	Closed	-$4.64M	–	45
2019 Q2	$4.64M	Buy	+316,900	New	+$4.64M	0.47%	32

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EcoR1 Capital's NGM Position: Q1 2024 in Review

EcoR1 Capital sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 2,385,873 shares — an estimated $2.05M sold.

EcoR1 Capital first reported a position in NGM in Q2 2019 and held it in 12 quarters. The position peaked at $32.3M in Q4 2022. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

EcoR1 Capital reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
EcoR1 Capital sold 2,385,873 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $2.05M.
EcoR1 Capital first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
EcoR1 Capital's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $32.3M in Q4 2022.
75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on EcoR1 Capital's 13F filing for Q1 2024, filed 15 May 2024.